A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema

Exclusion Criteria

• •Evidence of active or latent syphilis infection
• •Evidence of active or latent tuberculosis infection and/or positive tuberculosis assay, or previous or current HIV diagnosis
• •Serious acute or chronic medical or psychiatric illness
• •History of major ocular and non-ocular surgical procedures
• •Uncontrolled IOP or glaucoma or chronic hypotony
• •Any anatomical changes or media opacity in the study eye preventing evaluation of retina, vitreous, and capture of study images
• •Prior use of IVT biologics including anti-VEGFs less than 2-4 months prior to Day 1; received IVT Methotrexate within 4 months prior to Day 1
• •Prior macular laser therapy, cataract surgery within 6 months and laser capsulotomy within 3 months of Day 1
• •Topical corticosteroids and/or topical NSAID \> 3 drops per day in the 14 days prior to Day 1 (D1); intraocular or periocular corticosteroid injections in the 2 months prior to D1; subconjunctival corticosteroid injection within 1 month prior to Day 1; an OZURDEX implant in the 4 months prior to D1; YUTIQ, RETISERT or ILUVIEN implant in the 3 years prior to D1
• •Diagnosis of macular edema due to any cause other than NIU
• •Any major ocular conditions that may require medical or surgical intervention during the study period to prevent vision loss